Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply
Portfolio Pulse from
Plus Therapeutics has renewed its Master Services Agreement with Telix IsoTherapeutics Group to secure a reliable supply of the radioisotope Rhenium-186, crucial for its lead radiotherapeutic candidate.
December 03, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Plus Therapeutics has renewed its agreement with Telix IsoTherapeutics Group, ensuring a steady supply of Rhenium-186 for its lead product, potentially supporting its development and market readiness.
The renewal of the agreement ensures a reliable supply of a critical component for Plus Therapeutics' lead product, which is likely to positively impact the company's development timeline and investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90